Activator protein 1 (AP-1) and related inflammatory transcription complexes (AP-1)

Activator protein 1 (AP-1) is a heterogeneous transcription factor complex, most commonly existing as a heterodimer of Jun and Fos family proteins, which belong to the basic leucine zipper (bZIP) class. It serves as a critical integrator of various signaling pathways, including the mitogen-activated protein kinase (MAPK) cascades, to regulate genes involved in cell proliferation, differentiation, and the stress response (UniProt P05412, P01100). In the context of inflammation, AP-1 works in concert with other related complexes, such as Nuclear factor-kappa B (NF-kappaB), to drive the expression of inflammatory mediators including cytokines, chemokines, and matrix-degrading enzymes. Dysregulation of AP-1 activity is strongly linked to the progression of various cancers and chronic inflammatory disorders, including rheumatoid arthritis, psoriasis, and asthma (Zenz et al., 2008). Therapeutic strategies targeting AP-1 and its associated inflammatory complexes include the use of glucocorticoids, which mediate transrepression of AP-1 through direct protein-protein interactions, and small-molecule inhibitors like T-5224 that are designed to block its DNA-binding activity. Other approaches involve inhibiting upstream kinases or using retinoids to antagonize AP-1 function. However, because AP-1 is essential for many normal physiological processes and tissue homeostasis, achieving therapeutic selectivity remains a significant challenge, with potential risks of systemic toxicity and impaired immune function (Shaulian & Karin, 2002; Hess et al., 2004).

Other names

AP-1Activator protein-1Jun-Fos complexAP1 transcription factor complexAP-1/NF-kappaB complex

Drugs targeting the AP-1 complex and related inflammatory transcription complexes primarily act by disrupting DNA binding, preventing the dimerization of constituent subunits (such as Jun and Fos), or through transrepression mediated by nuclear receptors like the glucocorticoid receptor. Additionally, inhibitors may target upstream activating kinases, such as c-Jun N-terminal kinases (JNK), to prevent the phosphorylation and subsequent activation of the transcription factor complex (Hess et al., 2004; Shaulian & Karin, 2002).